Journal
EMBO REPORTS
Volume 21, Issue 2, Pages -Publisher
WILEY
DOI: 10.15252/embr.201949351
Keywords
broadly neutralizing antibodies; complement; HIV-1
Categories
Funding
- Institut Pasteur
- ANRS
- Sidaction
- Vaccine Research Institute [ANR-10-LABX-77]
- Labex IBEID [ANR-10-IHUB-0002]
- TIMTAMDEN [ANR-14-CE14-0029]
- CHIKV-Viro-Immuno [ANR-14-CE14-0015-01]
- L'Oreal Sponsorship
- Gilead HIV cure program
- European Research Council (ERC) [ERC-2013-StG 337146]
- G5 Institut Pasteur Program
- Milieu Interieur Program [ANR-10-LABX-69-01]
- INSERM
- French Ministry of Higher Education, Research and Innovation
Ask authors/readers for more resources
The effect of anti-HIV-1 antibodies on complement activation at the surface of infected cells remains partly understood. Here, we show that a subset of anti-Envelope (Env) broadly neutralizing antibodies (bNAbs), targeting the CD4 binding site and the V3 loop, triggers C3 deposition and complement-dependent cytotoxicity (CDC) on Raji cells engineered to express high surface levels of HIV-1 Env. Primary CD4 T cells infected with laboratory-adapted or primary HIV-1 strains and treated with bNAbs are susceptible to C3 deposition but not to rapid CDC. The cellular protein CD59 and viral proteins Vpu and Nef protect infected cells from CDC mediated by bNAbs or by polyclonal IgGs from HIV-positive individuals. However, complement deposition accelerates the disappearance of infected cells within a few days of culture. Altogether, our results uncover the contribution of complement to the antiviral activity of anti-HIV-1 bNAbs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available